Form 4: Gain Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Director Jeffrey Scott Riley acquired 15,000 stock options in Gain Therapeutics, Inc. on June 24, 2024.
Summary
- On June 24, 2024, Jeffrey Scott Riley, a director of Gain Therapeutics, Inc., acquired 15,000 stock options.
- The exercise price of these options is $1.29.
- The options vest in 12 equal monthly installments starting July 24, 2024, contingent upon continuous service.
- The options expire on June 24, 2034.
- Following the transaction, Riley directly owns 15,000 derivative securities.
Sentiment
Score: 5
Explanation: Neutral sentiment as it reports a routine transaction of stock options.
Industry Context
This is a standard Form 4 filing, reflecting a director's acquisition of stock options, a common practice in executive compensation within the biotechnology industry.
Key Dates
| Date | Description |
|---|---|
| 06/24/2024 | Date of transaction: Director acquired stock options |
| 07/24/2024 | Vesting start date for the stock options |
| 06/24/2034 | Expiration date of the stock options |
| 06/26/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.